News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
NeurogesX, Inc. Sets IPO at 4 Million Shares, $13-$15 Each
April 17, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, April 17 (Reuters) - Biopharmaceutical firm NeurogesX Inc. on Tuesday set its planned initial public offering at 4 million shares for an estimated price of $13 to $15 each.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
China
Recently Launched Third Arc Turns to China for Cancer T Cell Engagers
November 13, 2025
·
2 min read
·
Tristan Manalac
Drug Development
Five Trends That Got Everyone Talking in Pharma and Biotech This Year
November 12, 2025
·
5 min read
·
Jennifer Smith-Parker
Gene therapy
Lilly Doubles Down on Eye Diseases, Adding to BD Spree
November 10, 2025
·
1 min read
·
Annalee Armstrong
Metabolic disorders
Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases
November 10, 2025
·
2 min read
·
Tristan Manalac
